The latest TB-500 news adds a rat tendon study and a July FDA ingredient review. Neither establishes a benefit for people with an injury. TB-500 and its parent molecule, thymosin beta-4, also remain different substances. A new paper about the parent doesn't settle questions about the fragment.
Changelog
As of September 30, 2026, the day this article was written, July–September brought new animal findings and a review of raw ingredients for prescription medicines, without human TB-500 treatment results.
September 21, 2026: the sports entry stays
The 2027 World Anti-Doping Agency list, published September 21, keeps TB-500 prohibited during and outside competition; our WADA 2027 explainer covers athletes' prescription questions.
August 17, 2026: new research on the parent molecule
A Molecular Biomedicine study tested a lab-produced version of full-length thymosin beta-4 in mice with intestinal inflammation and scarring. The authors reported less damage and scarring. The treatment experiment involved mice; it wasn't a trial of TB-500 in patients.
August 11, 2026: a sports-medicine review
A 2026 review in the American Journal of Sports Medicine examined six popular peptides, short chains of amino acids, the building blocks of proteins. Thymosin beta-4 or TB-500 was among them. About two-thirds of the publications used animals: 67%. The authors found that claims about injury recovery and performance remained unsupported by current human trials. A review gathers existing studies; it isn't a new treatment trial.
July 23, 2026: a rat tendon experiment
In Biçer and colleagues' Joint Diseases and Related Surgery study, 32 male rats underwent repair of the Achilles tendon, at the back of the ankle. At four weeks, repaired tendons in the TB-500 group withstood more force before breaking than those in rats given neither peptide. Combining BPC-157 with TB-500 added no benefit over either alone in this experiment.
July 23, 2026: FDA's ingredient review
An FDA advisory committee considered two chemical forms of TB-500 for the 503A Bulks List, a list of raw ingredients for pharmacies preparing medication against individual prescriptions. FDA evaluated wound healing. The committee gives advice FDA doesn't have to follow. An ingredient review does not approve a medicine. Our TB-500 FDA review covers the regulatory history.
What TB-500 is
TB-500 is a lab-made fragment of thymosin beta-4. The fragment FDA reviewed has seven amino acids. Full-length thymosin beta-4 has 43.
A 2012 chemical analysis by Esposito and colleagues identified the fragment in material sold as TB-500. Its sequence is written Ac-LKKTETQ, lab shorthand for those seven building blocks with a small chemical cap at one end.
Thymosin beta-4 interacts with actin, the structural protein that helps cells change shape and move. That biology helps explain the interest in tissue repair. It doesn't tell us whether injecting the short fragment helps an injured person.
The thymosin beta-4 explainer separates the parent protein's studies from the fragment's. A full-length protein, an eye-drop preparation and an injected fragment each need evidence for the actual preparation being used.
What the TB-500 news means for recovery
The tendon paper adds an animal result worth following. It doesn't answer whether TB-500 helps a person recover from an injury.
In the full paper, the authors called their test material TB-500 but did not report its amino-acid sequence. That leaves a question about the exact preparation tested.
All the rats had surgery before treatment. Researchers then examined the tendons at one time point. They did not measure walking, a return to activity or later reinjury. Those are different questions from how much force a removed tendon withstands.
The animals were also healthy young males. A person's injury may come with age, diabetes, other medicines or months of symptoms. Those differences matter when deciding whether an experiment can inform treatment.
Four weeks in a rat study is therefore not a recovery deadline for a person. Nor does the experimental dose establish a human prescription. The provider sets any dose and follow-up plan from the individual evaluation.
What the rat study says about Wolverine
Wolverine combines BPC-157 and TB-500 in one injectable vial. Its blend explainer covers what that pairing contains.
The new experiment is useful because it tested the combination as well as each compound separately. The combination did not improve the measured outcomes beyond either compound alone. That finding gives no basis for assuming that two peptides make recovery faster.
It also doesn't settle every possible use of the pair. A small animal experiment cannot choose between a single compound and a blend for an individual patient. That would require better evidence about the actual preparation, the condition being treated and outcomes that matter to people.
Where FDA's compounding review stands
TB-500 is coming soon to Promise as a compounded medication, which is different from an FDA-approved product. The formulation Promise will offer is not FDA-approved. Compounding means a pharmacy prepares a medication against a prescription; it does not turn the preparation into an approved drug.
As of September 30, 2026, the day this article was written, FDA had published no proposed or final rule adding TB-500 to the list. The Federal Register's July–September TB-500 search returned no documents.
FDA's 503A compounding page, marked "Content current as of: 05/14/2026," describes list additions through public rulemaking. The July discussion did not itself change that list.
A licensed provider may still prescribe a compounded formulation when the applicable rules allow; that decision is between the patient and the doctor. Federal and state rules also apply to the pharmacy filling the prescription.
What a provider considers
The first question is what needs treating. A recent tendon tear, a long-standing sore joint and general training fatigue call for different evaluations. A provider weighs the diagnosis, previous treatment, current medicines, allergies and the recovery plan already in place.
FDA's May 15, 2026 briefing found no human treatment studies of the fragment and flagged possible immune reactions related to clumping and impurities. It also described inconsistent naming. Those findings make the exact ingredient and pharmacy documentation meaningful questions.
A prescription provides a clinician responsible for the decision and a pharmacy identified on the label. The conversation can cover the intended outcome, how it will be assessed and whom to contact about an unexpected reaction.
At Promise, a licensed provider reviews every request and may prescribe or decline; not everyone qualifies.
What would change this update
A proposed or final FDA rule would change the compounding record. A well-designed human trial of the identified TB-500 fragment would change the treatment evidence. Another positive experiment on the parent protein would still answer a different question.
For someone considering care now, the useful discussion is concrete: what condition is being treated, what evidence fits it and how the provider will judge progress. A news headline can start that conversation. It cannot supply the treatment decision.
